Results 101 to 110 of about 5,946,067 (288)

Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.

PLoS ONE, 2015
Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone.
Anja Verhulst, Shuting Sun, Charles E McKenna, Patrick C D'Haese   +3 more
doaj   +1 more source

Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial

Journal of Bone and Mineral Research, 2020
Androgen deprivation therapy (ADT) given to men with prostate cancer causes rapid and severe sex steroid deficiency, leading to increased bone remodeling and accelerated bone loss.
A. Cheung, R. Hoermann, A. Ghasem-Zadeh, A. J. Tinson, Vivian Ly, S. Milevski, D. Lim Joon, J. Zajac, E. Seeman, M. Grossmann   +9 more
semanticscholar   +1 more source

Incidence and Risk Factors of Serious Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia: A CYP‐C Population‐Based Study

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background Osteonecrosis (ON) is a debilitating complication of acute lymphoblastic leukemia (ALL) therapy. While numerous studies have explored its incidence and associated risk factors, investigations using large‐scale cohorts remain important to characterize ON across heterogeneous populations.
Noémie de Villiers, Chantal Éthier, Caroline Laverdière, Nathalie Alos, Thai Hoa Tran, Marie‐Claude Pelland‐Marcotte   +5 more
wiley   +1 more source

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Journal of Bone Oncology, 2019
Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj   +1 more source

Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis [PDF]

, 2017
Background Bisphosphonates exhibit direct antitumor activity in animal models, but only at high doses that are incompatible with the clinical dosing regimens approved for the treatment of cancer patients with skeletal metastases.
Clézardin, Philippe, Daubiné, Florence, Gasser, Juerg, Green, Jonathan, Le Gall, Céline   +4 more
core  

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial [PDF]

, 2013
BACKGROUND: The presence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients is associated with reduced clinical outcome. Bisphosphonate treatment was shown to eradicate DTC from BM in several studies.
Bernhard Kraemer, Birgit Wackwitz, Diethelm Wallwiener, Erich-Franz Solomayer, Gerhard Gebauer, Hans-Joachim Lueck, Jens Huober, Malgorzata Banys, Natalia Krawczyk, Peter Hirnle, Sven Becker, Tanja Fehm, Wolfgang Janni   +12 more
core   +2 more sources

Zoledronic acid promotes TLR‐4‐mediated M1 macrophage polarization in bisphosphonate‐related osteonecrosis of the jaw

The FASEB Journal, 2019
Bisphosphonate‐related osteonecrosis of the jaw (BRONJ) is a detrimental side effect of the long‐term administration of bisphosphonates. Although macrophages were reported to be an important mediator of BRONJ, the detailed potential mechanism of BRONJ ...
Weiwen Zhu, Rongyao Xu, Jinying Du, Yu Fu, Sheng Li, Ping Zhang, Laikui Liu, Hongbing Jiang   +7 more
semanticscholar   +1 more source

Bone scan index rise prior to osteonecrosis of the jaw with bone‐modifying agents in prostate cancer

BJUI Compass, Volume 7, Issue 5, May 2026.
Abstract Objective This study aimed to evaluate the maximum bone scan index in the jaw (BSIJmax) before the development of clinical medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer. Methods We retrospectively analysed 135 patients with prostate cancer and bone metastases who received bone‐modifying agents (BMAs ...
Masaru Tani, Koji Hatano, Takashi Kamiya, Masatoshi Konishi, Atsuki Matsukawa, Hiromu Horitani, Syunsuke Inoguchi, Tomohiro Kanaki, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Toshiki Oka, Yohei Okuda, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Tadashi Watabe, Atsunari Kawashima, Kayako Isohashi, Norio Nonomura   +22 more
wiley   +1 more source

Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles

International Journal of Nanomedicine, 2013
Li Chen,1 Yunfei Ding,2 Yongzhong Wang,3 Xingrong Liu,2 RJ Babu,1 WR Ravis,1 Weili Yan21Department of Pharmaceutical Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 2Department of Pharmaceutical Sciences, College of Life ...
Yan W, Ravis WR, Babu RJ, Liu X, Wang Y, Ding Y, Chen L   +6 more
doaj  

Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo [PDF]

, 2015
Clinical trials have shown that adjuvant Zoledronic acid (ZOL) reduces the development of bone metastases irrespective of ER status. However, post-menopausal patients show anti-tumour benefit with ZOL whereas pre-menopausal patients do not.
Eaton, C.L., Evans, C.A., Fowles, A., Holen, I., Nutter, F., Ottewell, P.D., Walker, M.   +6 more
core   +1 more source